Ultra-Short Course of Neo-Adjuvant Denosumab for Nerve-Sparing Surgery for Giant Cell Tumor of Bone in Sacrum

Spine (Phila Pa 1976). 2022 May 1;47(9):691-701. doi: 10.1097/BRS.0000000000004318. Epub 2021 Dec 27.

Abstract

Study deign: This was a retrospective study about sacral giant cell tumor of bone (GCTB).

Objective: This study aimed to investigate whether ultra-short course of neo-adjuvant denosumab treatment for sacral GCTB could (1) induce radiological and histological response? (2) Facilitate nerve-sparing surgery? (3) Achieve satisfactory oncological and functional outcomes?

Summary of background data: Previous reports on long course of neo-adjuvant denosumab treatment for GCTB showed significant tumor response and a relatively high recurrent rate after curettage.

Methods: Sixty-six patients with sacral GCTB treated with neoadjuvant denosumab and nerve-sparing surgery were categorized into ultra-short course group (≤3 doses and operation within D21 since 1st dose, 41 patients) or conventional group (>3 doses or operation after D21 since 1st dose, 25 patients). The radiological and histological response, operative data, oncological and functional outcomes were compared.

Results: The ultra-short course group demonstrated fewer doses of neo-adjuvant denosumab (mean: 2.1 vs. 4.8, P < 0.001) and shorter time to surgery (12.2 days vs. 72.3 days, P < 0.001). Similar patterns of radiological and histological response were observed in the two groups with less fibrosis and ossification in the ultra-short course group. The operative duration (199.9 min vs. 187.8 min, P = 0.364) and estimated blood loss (1552.4 mL vs. 1474.0 mL, P = 0.740) were comparable. Most (94.8%) of the patients received adjuvant denosumab. After a mean follow-up of 29.4 months, three cases (8.8%) and five cases (20.8%) showed local recurrence in each group (P = 0.255). The estimated recurrence-free survival (56.2 vs. 51.2 months, P = 0.210) and the functional status [Motor-Urination-Defecation scores: 25.9 vs. 25.7, P = 0.762] did not differ between the two groups.

Conclusion: Ultra-short course of neo-adjuvant denosumab for sacral GCTB could elicit radiological and histological responses as conventional course did. The less degree of fibrosis and ossification might facilitate nerve-sparing surgery and help to achieve satisfactory local control and functional status.Level of Evidence: 4.

MeSH terms

  • Bone Density Conservation Agents* / therapeutic use
  • Bone Neoplasms* / diagnostic imaging
  • Bone Neoplasms* / drug therapy
  • Bone Neoplasms* / surgery
  • Denosumab / therapeutic use
  • Fibrosis
  • Giant Cell Tumor of Bone* / diagnostic imaging
  • Giant Cell Tumor of Bone* / drug therapy
  • Giant Cell Tumor of Bone* / surgery
  • Humans
  • Neoadjuvant Therapy / adverse effects
  • Neoplasm Recurrence, Local / surgery
  • Retrospective Studies
  • Sacrum / diagnostic imaging
  • Sacrum / surgery

Substances

  • Bone Density Conservation Agents
  • Denosumab